ארצות הברית - אנגלית - NLM (National Library of Medicine)

darmerica, llc - butylscopolamine bromide (unii: 0gh9jx37c8) (butylscopolamine bromide - unii:0gh9jx37c8) -

ארצות הברית - אנגלית - NLM (National Library of Medicine)

darmerica, llc - butylscopolamine bromide (unii: 0gh9jx37c8) (butylscopolamine - unii:2z3e1of81v) -

פנמה - אנגלית - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorio sanderson, s.a. - n-butilbromuro de escopolamina - n-butilbromuro de escopolamina....20mg

ארצות הברית - אנגלית - NLM (National Library of Medicine)

baxter healthcare corporation - scopolamine (unii: dl48g20x8x) (scopolamine - unii:dl48g20x8x) - transderm scōp® is indicated in adults for prevention of nausea and vomiting associated with motion sickness.[see clinical studies (14.1)] transderm scōp® is indicated in adults for prevention of nausea and vomiting associated with recovery from anesthesia and/or opiate analgesia and surgery. [see clinical studies (14.2)] transderm scōp® is contraindicated in the following populations: pregnancy category c based on data from one prospective study of transderm scōp® in cesarean delivery, the rate of newborn adverse events in both the transderm scōp® and placebo groups were the same. the rates were 10.5% (12 events in 114 newborns) in both treatment groups. none of these events were considered life threatening or drug related. jaundice was the only adverse event occurring more frequently with transderm scōp® than placebo: 9 events (7.9%) versus 2 events (1.8%) (p=0.031). jaundice, a common occurrence in newborns, resolved with ultraviolet light and did not prolong the hospital stay. there are no adequ

ארצות הברית - אנגלית - NLM (National Library of Medicine)

glaxosmithkline consumer healthcare holdings (us) llc - scopolamine (unii: dl48g20x8x) (scopolamine - unii:dl48g20x8x) - transderm scōp is indicated in adults for the prevention of: transderm scōp is contraindicated in patients with: risk summary available data from observational studies and postmarketing reports with scopolamine use in pregnant women have not identified a drug associated risk of major birth defects, miscarriage, or adverse fetal outcomes. avoid use of transderm scōp in pregnant women with severe preeclampsia because eclamptic seizures have been reported after exposure to scopolamine (see data). in animal studies, there was no evidence of adverse developmental effects with intravenous administration of scopolamine hydrobromide revealed in rats. embryotoxicity was observed in rabbits at intravenous doses producing plasma levels approximately 100 times the levels achieved in humans using a transdermal system. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u

אירלנד - אנגלית - HPRA (Health Products Regulatory Authority)

roche products ltd - papaverine hyoscine hydrobromide - withdrawn form

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - hyoscine 0.4 mg/ml; papaveretum 20 mg/ml - solution for injection - 0.4mg,20mg/ml - active: hyoscine 0.4 mg/ml papaveretum 20 mg/ml

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

viatris limited - hyoscine 1.45mg equivalent to scopolamine;   - transdermal patch - active: hyoscine 1.45mg equivalent to scopolamine   excipient: = pigmented poylethylene/polyester film (mediflex® 1501) = transparent fluoropoylmer coated polyester release liner (scotchpak 1022 or scotchpak 9709) no tox ink brown- fgn4476 polypropylene povidone silicone adhesive - for the prevention of symptoms of motion sickness, such as nausea, vomiting and vertigo, which can occur when travelling.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

tps - scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x), propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - take one tablet orally as directed by your physician as needed for symptoms of panic or anxiety. do not exceed two tablets per day.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

prasco laboratories - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - • glaucoma; • obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); • obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); • paralytic ileus, intestinal atony of the elderly or debilitated patient; • unstable cardiovascular status in acute hemorrhage; • severe ulcerative colitis especially if complicated by toxic megacolon; • myasthenia gravis; • hiatal hernia associated with reflux esophagitis; • in patients with known hypersensitivity to any of the ingredients. phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement. phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs (see warnings ). in patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsion